Analyst Insights - Digital Health Posts

Read our Analysts’ insights and expert opinions on the latest healthcare technology industry developments and market trends. Signify Research provides both free insights and premium insights which are only available to subscribers of "Signify Premium Insights".
Click on the premium insights link below to filter for just the premium content.



Signify Premium Insight: The Key Trends of RSNA 2021: Imaging IT

Signify Premium Insights Subscription Required

15th October 2021 – The RSNA Annual Meeting is rapidly approaching, with vendors soon returning to the Chicago exhibition hall for the first time since 2019. This Premium Insight details the trends and developments that medical imaging IT vendors are set to be showing off at the event.

Signify Premium Insight: FDA Approval Lets Siemens Make CT Count

Signify Premium Insights Subscription Required

13th October 2021 – Siemens Healthineers has become the first medical imaging vendor to have a photon-counting CT scanner cleared by the FDA. The regulator praised the system as the “first major new technology for computed tomography imaging in nearly a decade,” but what does it mean for the market?

Strength in Union: Medica and Vital Radiology’s Partnerships to Bolster NHS

11th October 2021 – Two key deals, involving four of the UK and Oceania’s teleradiology providers, were announced in early 2021. Signify Research provides its take on these deals in this insight.

Signify Premium Insight: Philips’ Future Vision for Imaging: Digital Platforms, Service Line Efficiency & Long-Term Partnerships

Signify Premium Insights Subscription Required

7th October 2021 – At a recent analyst day, Philips detailed how it will transition to a digital future, in which a greater proportion of revenues are derived from services. This Premium Insight explores the strategy and highlights its key facets.

Signify Premium Insight: Addressing the Shortcomings of AI

Signify Premium Insights Subscription Required

5th October 2021 – A recent study appeared to dampen the excitement for medical imaging AI after concluding that some breast screening tools were a long way from having the quality or quantity of evidence required for their adoption into clinical practice. This Premium Insight adds context to this verdict and considers the other factors at play.